Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients

Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9 Wilson, 1980, Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols, Am J Cardiol, 46, 649, 10.1016/0002-9149(80)90516-0 Castelli, 1986, Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study, JAMA, 256, 2835, 10.1001/jama.1986.03380200073024 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Assmann, 1996, High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, 124, S11, 10.1016/0021-9150(96)05852-2 Ridker, 2010, HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial, Lancet, 376, 333, 10.1016/S0140-6736(10)60713-1 Ray, 2009, Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22, Arterioscler Thromb Vasc Biol, 29, 424, 10.1161/ATVBAHA.108.181735 Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med, 357, 1301, 10.1056/NEJMoa064278 deGoma, 2008, Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol, J Am Coll Cardiol, 51, 49, 10.1016/j.jacc.2007.07.086 Jafri, 2010, Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk, Ann Intern Med, 153, 800, 10.7326/0003-4819-153-12-201012210-00006 Boden, 2007, Optimal Medical Therapy with or without PCI for stable coronary disease, N Engl J Med, 356, 1503, 10.1056/NEJMoa070829 Maron, 2010, Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, J Am Coll Cardiol, 55, 1348, 10.1016/j.jacc.2009.10.062 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001 Boden, 2006, Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424, Am Heart J, 151, 1173, 10.1016/j.ahj.2005.08.015 1994, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), Circulation, 89, 1333, 10.1161/01.CIR.89.3.1333 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Libby, 2005, The forgotten majority: unfinished business in cardiovascular risk reduction, J Am Coll Cardiol, 46, 1225, 10.1016/j.jacc.2005.07.006 LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461 Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Deedwania, 2006, Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study, Lancet, 368, 919, 10.1016/S0140-6736(06)69292-1 Olsson, 2005, High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL Trial, Eur Heart J, 26, 890, 10.1093/eurheartj/ehi186 Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585 Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579 Armitage J, for the HPS2-THRIVE Collaborative Group. HPS2-THRIVE: Randomized placebo-controlled trial of ER Niacin and laropriprant in 25,673 patients with pre-existing cardiovascular disease. Abstract presented at: American College of Cardiology Scientific Session 2013; March 9, 2013; San Francisco, CA. Cannon, 2009, Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib, Am Heart J, 158, 513, 10.1016/j.ahj.2009.07.028 Eli Lilly and Company. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE). Available at: http://clinicaltrials.gov/show/NCT01687998. Accessed March 24, 2013. Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797 deGoma, 2012, High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein?, J Am Coll Cardiol, 60, 517, 10.1016/j.jacc.2012.03.058